# CareMark Comp
**Opioid Management Program**
**Effective: July 1, 2017**
**For SAIF Injured Workers Enrolled in CareMark Comp**

<table>
<thead>
<tr>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
</tr>
</thead>
</table>
| • Workers prescribed Short-Acting Opioids ≤ 90 mg MED for up to 6 weeks.  
• Workers prescribed Long-Acting Opioids for up to 1 week post-surgery. | • BEFORE prescribing Short-Acting Opioids beyond 6 weeks duration.  
• BEFORE initiating Long-Acting Opioids whether or not on Short-Acting Opioids. Includes surgery patients more than 1 week post-surgery. | Workers already on Long-Acting and/or Short-Acting Opioids ≤ 90 mg MED on July 1, 2017 or when enrolled on or after July 1, 2017. | Workers already on Long-Acting and/or Short-Acting Opioids > 90 mg MED on July 1, 2017 or when enrolled on or after July 1, 2017. |
| **NO PRECERT REQUIRED** | **PRECERT REQUIRED** | **NO PRECERT REQUIRED TO CONTINUE ≤90 MG MED** | **PRECERT REQUIRED TO INCREASE DOSAGE ALREADY > 90 MG MED TO HIGHER DOSAGE** |
| Caution: Be aware there are associated risks and the goal should be short-term use with a date/plan to discontinue the opioid.  
There is some indication for medically appropriate use of Long-Acting Opioids post-surgery short-term for no more than 1 week post-surgery. | | FOR worker already on Long-Acting and/or Short-Acting Opioids up to 90 mg MED on July 1, 2017 or when enrolled on or after July 1, 2017, no precertification required if dosage does not exceed 90 mg MED. Precertification required prior to increasing dosage above 90 mg MED for Long-Acting and/or Short-Acting Opioids. | Precertification required prior to increasing dosage for worker already on Long-Acting and/or Short-Acting Opioids at dosage exceeding 90 mg MED on July 1, 2017 or when enrolled on or after July 1, 2017, before increasing dosage even higher.  
Precertification includes referral to AP’s choice among 4 pain physicians for consultation.  
|| | Precertification includes referral to AP’s choice among 4 pain physicians for consultation. |
| | | Recertification of previously precertified and approved opioids. Precertification approval process must be repeated to continue prescribing beyond date range of current precert approval or at least annually, whichever comes first. |

## DOCUMENTATION REQUIRED FOR PRECERTIFICATION

<table>
<thead>
<tr>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
</tr>
</thead>
</table>
| • Opioid Risk Assessment  
• Urine Drug Analysis (CCLAO-CareMark Comp LAO Panel)  
• Signed Medication Agreement  
• Signed Material Risk Notice  
• Initiate VAS/Function monitoring  
• Process monitored by forms | • Opioid Risk Assessment  
• Urine Drug Analysis (CCLAO-CareMark Comp LAO Panel)  
• Signed Medication Agreement  
• Signed Material Risk Notice  
• Initiate VAS/Function monitoring  
• Process monitored by forms  
• Pain Physician Consultation | • Opioid Risk Assessment  
• Urine Drug Analysis (CCLAO-CareMark Comp LAO Panel)  
• Signed Medication Agreement  
• Signed Material Risk Notice  
• Initiate VAS/Function monitoring  
• Process monitored by forms  
• Pain Physician Consultation | • Opioid Risk Assessment  
• Urine Drug Analysis (CCLAO-CareMark Comp LAO Panel)  
• Signed Medication Agreement  
• Signed Material Risk Notice  
• Initiate VAS/Function monitoring  
• Process monitored by forms  
• Pain Physician Consultation |